Glenmark starts clinical trials for potential Covid-19 drug
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Glenmark Pharmaceuticals, the first company in the country to initiate Phase 3 clinical trials on antiviral drug Favipiravir to check its efficacy on COVID-19 patients in India.

• Received approval from Drug Controller General of India (DCGI) in April
• Clinical trials have commenced and over ten leading government and private hospitals are being enrolled for the study
• Estimates study completion by July-August 2020
• 150 subjects with mild to moderate COVID-19 symptoms will be randomized in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care.
• Treatment duration is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomization.

P●●●●i P●●●●●n and 17 others like this9 shares